Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

Jonathan Pol; Guido Kroemer

doi:10.1038/S41422-018-0031-9

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

Jonathan Pol, Guido Kroemer

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

15 Citations (Scopus)

Résumé

A CTLA-4-specific antibody, ipilimumab, is clinically used in anticancer immunotherapy, yet induces severe autoimmune side effects. Two papers by Du et al. published recently in Cell Research now suggest strategies for potentially uncoupling toxicity and efficacy of CTLA-4-targeting antibodies.

langue originale	Anglais
Pages (de - à)	501-502
Nombre de pages	2
journal	Cell Research
Volume	28
Numéro de publication	5
Les DOIs	https://doi.org/10.1038/S41422-018-0031-9
état	Publié - 1 mai 2018

Accès au document

10.1038/S41422-018-0031-9

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{65ea7ad8585d47f79edbd53fc2ea980e,

title = "Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy",

abstract = "A CTLA-4-specific antibody, ipilimumab, is clinically used in anticancer immunotherapy, yet induces severe autoimmune side effects. Two papers by Du et al. published recently in Cell Research now suggest strategies for potentially uncoupling toxicity and efficacy of CTLA-4-targeting antibodies.",

author = "Jonathan Pol and Guido Kroemer",

note = "Publisher Copyright: {\textcopyright} The Authors.",

year = "2018",

month = may,

day = "1",

doi = "10.1038/S41422-018-0031-9",

language = "English",

volume = "28",

pages = "501--502",

journal = "Cell Research",

issn = "1001-0602",

number = "5",

}

TY - JOUR

T1 - Anti-CTLA-4 immunotherapy

T2 - uncoupling toxicity and efficacy

AU - Pol, Jonathan

AU - Kroemer, Guido

N1 - Publisher Copyright: © The Authors.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - A CTLA-4-specific antibody, ipilimumab, is clinically used in anticancer immunotherapy, yet induces severe autoimmune side effects. Two papers by Du et al. published recently in Cell Research now suggest strategies for potentially uncoupling toxicity and efficacy of CTLA-4-targeting antibodies.

AB - A CTLA-4-specific antibody, ipilimumab, is clinically used in anticancer immunotherapy, yet induces severe autoimmune side effects. Two papers by Du et al. published recently in Cell Research now suggest strategies for potentially uncoupling toxicity and efficacy of CTLA-4-targeting antibodies.

UR - http://www.scopus.com/inward/record.url?scp=85065492625&partnerID=8YFLogxK

U2 - 10.1038/S41422-018-0031-9

DO - 10.1038/S41422-018-0031-9

M3 - Article

C2 - 29593340

AN - SCOPUS:85065492625

SN - 1001-0602

VL - 28

SP - 501

EP - 502

JO - Cell Research

JF - Cell Research

IS - 5

ER -